|
| Publications [#132161] of James M Provenzale
Papers Published
- I Cokgor, G Akabani, HS Friedman, AH Friedman, MR Zalutsky, LM Zehngebot, JM Provenzale, CD Guy, CJ Wikstrand, DD Bigner, Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study.,
Cancer, United States, vol. 91 no. 9
(May, 2001),
pp. 1809-13, ISSN 0008-543X
(last updated on 2007/02/06)
Abstract:
Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46-year-old white female who presented with progressive hearing loss, severe headaches, nausea, vomiting, and a rapid decline in neurologic status. She was referred to Duke University Medical Center after conventional chemotherapy for malignant melanoma failed. She was enrolled in a Phase I trial of (131)I-labeled monoclonal antibody Mel-14 F(ab')(2) fragment administered intrathecally. Within a year after her treatment, she recovered, having a normal neurologic exam except for residual bilateral hearing loss. The authors discuss dosimetry, preclinical, and clinical studies conducted with Mel-14 F(ab')(2) and introduce a potentially promising therapy option in the treatment of neoplastic meningitis in patients with malignant melanoma. Currently, the patient remains neurologically normal except for a mild bilateral hearing loss more than 4 years after treatment and has no radiographic evidence of neoplastic meningitis.
Keywords:
Antibodies, Monoclonal • Chondroitin Sulfates • Female • Humans • Iodine Radioisotopes • L-Selectin • Melanoma • Meningitis • Middle Aged • Radiopharmaceuticals • adverse effects • etiology* • immunology • radiotherapy* • therapeutic use*
|
